> 首页 > 产品 > 一抗 > 基因重组 > Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin)

Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin)

Recombinant Antibody

Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 90%.
The purity of Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab vedotin) is more than 95%, determined by SEC-HPLC.
Immobilized human Siglec 2 / CD22, His Tag at 2 ug/mL can bind Anti-Siglec-2 / CD22 Reference Antibody (Pinatuzumab vedotin), EC50=0.008851 ug/mL.
The drug-to-antibody ratio (DAR) of the Anti-Siglec-2 / CD22 Reference Antibody (Pinatuzumab vedotin) is 4.3.
Human Siglec-2 / CD22 HEK293 Cell Line were stained with Anti-Siglec-2 / CD22 Reference Antibody (Pinatuzumab vedotin) and negative control protein respectively, washed and then followed by PE and analyzed with FACS,The EC50 is 0.21 µg/mL.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P20273
Reactivity	Human
Clonality	ADC
Isotype	IgG1
Calculated MW	95348 Da

Additional Information
Target/Specificity	Siglec-2 / CD22
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	MMAE
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Protein Information
Name	CD22 {ECO:0000303\|PubMed:1691828, ECO:0000312\|HGNC:HGNC:1643}
Function	Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed:34330755, PubMed:8627166). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed:20172905). Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling (PubMed:8627166). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed:20516366).
Cellular Location	Cell membrane; Single-pass type I membrane protein
Tissue Location	B-lymphocytes.